Cowen and Company’s Kura Oncology KURA Stock Holding History

Cowen and Company’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,853	Closed	-$96K	–	681
2021 Q4	$96K	Buy	+6,853	New	+$111K	0.01%	374

Other funds holding KURA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Cowen and Company's KURA Position: Q1 2022 in Review

Cowen and Company sold out of Kura Oncology (KURA) in Q1 2022, closing a stake of 6,853 shares — an estimated $96K sold.

Cowen and Company first reported a position in KURA in Q4 2021 and held it in 1 quarter. The position peaked at $96K in Q4 2021. 152 funds tracked by Wall St. Rank hold KURA as of Q1 2022.

Cowen and Company reported no remaining Kura Oncology position as of Q1 2022 after selling out during the quarter.
Cowen and Company sold 6,853 Kura Oncology shares in Q1 2022, an estimated $96K.
Cowen and Company first reported a position in Kura Oncology in Q4 2021 and held it in 1 quarter.
Cowen and Company's Kura Oncology position peaked at $96K in Q4 2021.
152 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.